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Biomarkers as parameters of pathophysiological conditions can be of outmost relevance
for inflammatory myopathies. They are particularly warranted to inform about diagnostic,
prognostic, and therapeutic questions. As biomarkers become more and more relevant
in daily routine, this review focusses on relevant aspects particularly addressing
myopathological features. However, the level of evidence to use them in daily routine
at presence is low, still since none of them has been validated in large cohorts of
patients and rarely in independent biopsy series. Hence, they should be read as mere
expert opinions. The evaluation of biomarkers as well as key biological parameters is an
ongoing process, and we start learning about relevance of them, as we must recognize
that pathophysiology of myositis is biologically incompletely understood. As such this
approach should be considered an essay toward expansion of the definition “biomarker”
to myositis, an emerging field of interest in biomedical research.
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INFLAMMATORY MYOPATHIES
Inflammatory myopathies may relate to different groups of diseases comprising infectious ones,
those associated with other rheumatological or syndromic diseases affecting extramuscular systems
and the ones, which occur as sole organ affection (muscle affection) in the context of a defined
extramuscular disease. The group of inflammatorymyopathies sensu strictu is termed the idiopathic
inflammatory myopathies (IIMs) and they are again comprising heterogeneous entities (1–5).
For more than 40 years, the inflammatory myopathies (IIMs) have been assigned to either
polymyositis (PM) or dermatomyositis (DM) (6, 7), and sporadic inclusion body myositis has also
been included here. However, recently the spectrum of PM and DM has been rearranged, and this
was achieved on the basis of the definition of subgroups with homogeneous clinical symptoms like
e.g., the anti-synthetases syndrome and associated myositis (8–11). The sub-entities have also been
confirmed at the serum auto-antibody level (12) and at the morphological level (2).
APPROVED DEFINITION OF BIOMARKERS AND EXPANDED
DEFINITION OF BIOMARKERS
A biomarker is defined as an indicator of a certain physiological or pathophysiological
condition. Biomarkers may also inform about prognosis and therapeutic effectiveness in times
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of targeted therapy approaches. They are warranted if a
direct assessment of a condition or the function/dysfunction
of an organ is not easily accessible. It may also be useful
if time to render a firm diagnosis matters. Sensitivity and
specificity are of outmost relevance if we talk about biomarkers
and their interpretation. The National Institutes of Health
(NIH) propose the following definition: A biomarker is:
“a characteristic which is objectively measurable, indicating
normal or pathophysiological processes, or treatment response
to therapeutic intervention.” This implies two main items:
(i) a biomarker should be measurable with precision and
reliability. (ii) The potential indirect character of a biomarker
based on one or several biological parameters (e.g., genetic
characteristics, proteins, “key” molecules, metabolites, etc.),
which allow characterization/description of a physiological or
a pathological state, the evolution of a disease or its response
to treatment. This may be called the approved definition of
a biomarker.
In our daily practice, assessment of certain biomarkers is
part of routine exams (e.g., blood sugar), whereas others are
only assessed in very specific situations/diseases and measured
in highly specialized laboratories. The whole field of laboratory
medicine can be regarded as a biomarker repository for the
individual human being and can be evaluated over time. Just to
name some, in oncology we use enzymes (alkaline phosphatase)
and also tumor proteins and more recently genetic alterations
like BRACA to identify risk factors, activity of a cancer, or
acquire information on prognosis and even on therapeutic
decisions. The measurement of Dystrophin staining (intensity
and expansion) is an interesting example of what we would like
to call expanded definition of biomarker use. Dystrophin levels
cannot be assessed in the serum or cerebrospinal fluid of patients
to obtain information about the level of “left-over” dystrophin
as a measure of therapeutic success of modern dystrophin
replacement strategies.
Biomarkers we use in cardiology are Troponin to test cardiac
injury or NT proBNP to test cardiac failure, both markers can
be measured in the blood of patients. Levels of CD4+ cell
count and HIV viral burden are used to monitor HIV treatment
efficacy. Biomarkers we use in pulmonology are gasses like O2
and CO2. Biomarkers in forensic medicine may be blood alcohol
and liver enzymes. In neurodegenerative diseases, certain CSF
and blood parameters are indicative of disease activity, but it is
difficult to gain information about thresholds and early stages of
degenerative diseases.
Abbreviations: PFP, perifascicular pathology; ASS, Anti-synthetases syndrome;
ASSM, Anti-synthetases syndrome-associated myositis; MxA, Myxovirus A; EM,
Electron microscopy; ISG15, Interferon-stimulated gene 15; RIG1, retinoic acid
inducible gene I; CD56 NCAM, Neural cell adhesion molecule; MAC, C5b-9
Membrane attack complex; IIMs, Idiopathic inflammatory myopathies; MAA,
Myositis-associated autoantibodies; MSA, Myositis-specific autoantibodies; Anti-
M2, anti mitochondrial Antibodies; DM, dermatomyositis; IMNM, Immune-
mediated necrotizing myopathy; iRMyositis, immune checkpoint inhibitor-related
myositis; Anti-M2-asociated myositis Anti Mitochondrial antibody-associated
myositis; sIBM, sporadic inclusion body myositis; GVHD, graft vs. host disease;
AP, alkaline phosphatase; MHC-class I (-II), major histocompatibility complex.
If we take a look at chronic inflammatory diseases, we also
use a number of interesting biomarkers that may inform about
a certain entity: e.g., ANCAs in ANCA-associated vasculitis, and
less specific markers such as ANA antinuclear antibodies, ENA,
dsDNA etc., which just inform about connective tissue disorder
classification or anti-DNA titer and/or complement dosages
measuring disease activity in lupus erythematosus (13–15). In
modern diagnostic approaches to autoimmune encephalitis,
anti-neuronal antibodies like NMDA or LGI1 and CASPR2
(Anti-voltage gated potassium channel associated proteins)
are measurable in the serum and can be used as diagnostic
markers (e.g., in brain slice cultures of rodents) (16), because
for obvious reasons, the brain is not accessible to a biopsy
without considerable risk. Myasthenia gravis has highly specific
biomarkers such as e.g., anti-AchR or anti-MUSK antibodies
(17). However, in other chronic inflammatory CNS diseases
like multiple sclerosis, unfortunately there is no widely-accepted
highly specific marker in the serum. Instead, we generally use
CSF markers like oligoclonal bands (OCBs) that are not present
in serum, to achieve diagnostic certainty, although OCBs are not
at all specific for multiple sclerosis.
BIOMARKERS IN INFLAMMATORY
MYOPATHIES
If we want to define biomarkers we should ask for what
they may be useful, hence if we need them for diagnostic or
prognostic accuracy and clinical follow-up, or if we need them for
therapeutic decisions (as well), as a biomarker “companion with
medication.” The latter can be measured only once to establish
a certain therapy or multiple times during therapy to monitor
efficacy or toxicity.
Which Biomarkers Can Be Used in Muscle
Diseases?
Biomarkers in the narrower sense are considered to be
measurable in bodily liquids, however, there may also be
certain patterns: e.g., morphological patterns (2, 8, 18), or MRI-
patterns. The latter have attracted great interest, specifically in
congenital myopathies like core myopathies, and CMDs like
Ullrich muscular dystrophy to a point that they can predict
genetic mutations with high certainty (19).
MUSCLE ENZYMES AND RELATED
MOLECULES AS BIOMARKERS
There are five “muscle enzymes” including creatine kinase (CK),
transaminases: aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), lactate dehydrogenase (LDH), and
aldolase, which leak into the circulation from damaged muscle
leading to their elevation in serum.Moderate to high correlations
were observed among them (20). All of them have been used as
indirect markers of any condition inducing myolysis, including
the idiopathic inflammatory myopathies (IIM). Some of these
enzymes are more specific of muscle tissue (CK, aldolase),
while others are present in nearly all living cells (LDH) or in
Frontiers in Neurology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 554
Benveniste et al. Biomarkers in Myositis








PFP-DM(+++ – +/–) Mi2, TIF1γ, NXP2, SAE,
MDA5
DM
PFP-ASS(+++ – +) Jo1, PL7, PL12, OJ, EJ etc. ASSM









Dystrophy-like pattern with rimmed
vacuoles and inflammation
cN1a sIBM severe









PFP focal & focal
necrotic fibers
MAC predominant on sarcolemma Mi-2





Ghost fibers and punched-out
vacuoles








No or few ghost fibers and sparse
punched-out vacuoles
Few T cells, many
endomysial macrophages

















AP may be positive in perimysium

























MAC on sarcolemma T cells and few B cells Overlap Myositis with MAAs
like anti-KU,
-U1RNP, etc.
PFP-DM Perifascicular pathology characteristic for DM:
This is the core feature, which is unifying all subtypes of DM while distinguishing them from other IIMs: It can be identified by a combination of stains which highlight the physiological
effect of the Interferon type I-related pathology, loss of capillaries, atrophy of myofibers, fibers most often clustering in the perifascicular region during the course of disease, Non-specific
stains that can be used to highlight this pathology are neo Myosin heavy chain (MyHc), MHC class I, CD56, complement (C5b-9), utrophin, laminin alpha5 showing a characteristic
gradient: perifascicular toward the centrofascicular region. Sarcolemmal stains such as dystroglycans and laminin aloha 5 also show the sarcolemmal integrity of by far most atrophic
fibers. This feature may help to distinguish atrophic from necrotic fibers. Specific stains showing involvement of characteristic type I interferon-related pathology that should be used are
MxA, ISG15, RIG1 etc. highlighting, in most cases, a gradient as well, while sometimes staining may be more diffusely positive. EM highlights tubuloreticular inclusions in endothelial
cells and lymphocytes (level II evidence) (1–3).
PFP-ASS Perifascicular pathology characteristic for ASSM:
This is the core feature unifying all ASSM subtypes of which the most frequent ones are anti-JO1-associated myositis followed by anti-PL7, -PL12, -OJ, and rarely the remaining four
known ones. It can be identified by variably intense presence of necrotic myofibers confined to the perifascicular area and absence of necrotic fibers at the center of fascicles, and
absence of clusters of necrotic fibers or regional necrosis. Of note, there is absence of MxA staining of the perifascicular fibers. EM may highlight pathognomonic nuclear actin inclusions.
(level II evidence) (4–8).
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TABLE 2 | Non-specific and disease specific biomarkers in myositis.
Laboratory Biomarker Aim
Non-Disease specific CK, AST, ALT, LDH, and
aldolase, troponins, ferritin, KL6,
leukocytes, lymphocytes etc.
To differentiate the stage of a disease, evolution, effect of
therapy(?) and pathophysiology
MAAs Helps to differentiate the severity of disease or inform about
overlap features
Disease specific MSAs Helps to diagnose the subentity of IIMs
TIF1γ and MAC on capillaries TIF1γ-associated adult DM cancer is highly likely to ensue or
be present
TIF1γ but no MAC on capillaries TIF1γ-associated adult DM cancer is less likely
cN1A sIBM Marker of severity
Useful for diagnosis if clinical features or biopsy features are
non-conclusive or atypical
Janus Kinase (Jak)
Type I IFN signature
DM Helpful for diagnostic purposes
In the future may be helpful for selection of candidate
medication, which is likely to prove efficacy
Type I IFN signature (j)DM Helpful for diagnostic purposes
To identify or select individual patients who benefit from best
risk/benefit ratio of certain therapies
ASS-associated ABs ASSM No elevated cancer risk
Anti-SRP IMNM No elevated cancer risk
Anti-HMGCR IMNM 20–30% cancer
No detectable AB IMNM 30% cancer
FIGURE 1 | Characteristic example of anti-SRP+ IMNM. (A) Diffuse myofiber necrosis in different stages of single cell necrosis and regeneration (H&E stain, original
magnification x200). (B) MHC class I sarcolemmal stain with diffuse character (original magnification x200). (C) CD68+ macrophages confined to myophagocytosis
and diffusely distributed in the endomysium (original magnification x200). (D) C5b-9 complement deposition on the sarcolemma of myofibers (original magnification
x400).
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hepatocytes (transaminases). One of the most common causes
of CK elevation is eccentric exercise. Serum levels depend on
gender, muscle mass, exercise intensity, and duration in addition
to the individual training state, and there is a remarkable inter-
individual variability in the degree to which serum enzyme
activities increase with exercise (21, 22). Thus, one must first re-
test these enzymes at rest, at least 5–7 days after physical activity
or any eccentric exercise, as the peak of CK often occurs at 4
days delay (23). After excessively intense exercise, muscle enzyme
release cannot be used to predict the magnitude of muscle
function impairment caused by muscle necrosis (24). That is,
CK levels up to 100,000 IU/L can be perfectly asymptomatic or
reveal an exertional heat illness with rhabdomyolysis. Conversely,
some skeletal muscle diseases (Myotonic dystrophy, congenital
myotonia, neurogenic disorders and myasthenia) may not show
elevated CK levels at all while the clinical impairment can be very
considerable. Similar muscle enzyme leakage into the blood can
be observed in many muscle diseases with muscle fiber necrosis
from rhabdomyolysis (toxic, genetic, heat illness) to inherited
dystrophies or metabolic myopathies or IIM, as well as during
mechanical (25) or electrical (26) injuries.
Given these limitations, serum CK levels are generally good
markers of disease activity in myositis. However, in certain
forms of dermatomyositis (27) and inclusion body myositis (28)
patients’ CK levels can be slightly elevated or normal, completely
independent of muscle weakness or disease severity; so, they are
not suitable markers of disease activity in these conditions. In
DM patients, notably those with anti-Mi-2 antibodies, CK levels
appear elevated (often > 5,000 IU/L) at onset and normalize
with treatment (Landon-Cardinal O. Anti-Mi2 Dermatomyositis
Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and
High Risk of Malignancy. In: ACR Meeting Abstracts. Available
at: http://acrabstracts.org/abstract/anti-mi2-dermatomyositis-
revisited-pure-dm-phenotype-with-muscle-fiber-necrosis-
and-high-risk-of-malignancy/. Accessed January 31, 2017) so
following levels in individual patients is reasonable in Mi-2+
dermatomyositis. In patients with anti-Jo-1+ anti-synthetase
syndrome (29), and immune mediated necrotizing myopathies
with anti-SRP (30) or anti-HMGCR (31) antibodies, CK levels
clearly correlate with myofiber necrosis and thus disease activity
and should be used in the follow-up of the patients. CK levels
obviously do not allow for differentiation between IIMs and
other e.g., genetic/metabolic muscle diseases and they cannot be
used to differentiate between different IIM subtypes, although
some IIMs have tendency to show high CK levels than others
(IMNM>ASSM>DM, OM, NM>IBM).
Several other laboratory markers which are generally assessed
in routine blood exams can be used as biomarkers. Among
those are KL-6, ferritin, and troponins: KL-6 has been shown
to be useful biomarkers for monitoring activity and severity
of ILD in DM and PM as well as in jDM (32, 33). Ferritin
was analyzed as a biomarker with similar profile as KL-6 and
correlates well with treatment responsivity, specifically in anti-
MDA5-associated DM (34, 35). Troponins (serum Troponin T)
were assessed in addition to CK and CK-MB ratio early on in PM
and DM and are useful markers as well (36, 37) Also in sIBM the
heart and the value of assessing troponins was tested but was not
found different to an age-matched control group (38). TnT values
were elevated in another study however not reflecting cardiac
damage (39). All the cited serum biomarkers have mostly grade II
level of evidence (max. smaller randomized control trials or series
or case-control studies).
THE INTERFERON SIGNATURE AS
BIOMARKER
Transcriptomic studies carried out on biopsy specimens from
skeletal muscle from DM patients have shown a specific
up-regulation of multiple interferon-stimulated genes (ISG)
suggesting that type I interferons (IFN-I) play an important
role (40, 41). The expression of some interferon signature genes
(ISGs), such as MXA, ISG15, and RIG-I, has been confirmed at
the protein level in perifascicular regions and on the capillaries
of the muscle biopsies (40–44). DM patients harbor high levels
of circulating IFN-I cytokines including IFN-β (45) and IFN-α
(46, 47), and the disease activity positively correlates with ISG
transcript levels in the blood (48). In humans, there are five
different types of type I interferons (IFN-I): IFN-α, IFN-β, IFN-
ε, IFN-κ and IFN-ω (49). They are recognized by heterodimeric
receptor complexes, comprising IFN-α receptor (IFNAR1) and
IFNAR2 subunits that transduce signals to the nucleus by the
JAK/STAT complex resulting in the upregulation of hundreds
of different ISGs, including IFN-I cytokines, involved in anti-
viral defense (50). While the IFN-I pathway has been implicated
in the pathophysiology of DM for more than a decade, its role
in muscle and skin damage has been precisely explored only
recently (51). In vitro, the activation of IFN-I in differentiating
myoblasts abolished myotube formation with reduced myogenin
expression, while in differentiated myotubes, a reduction in
surface area and an upregulation of atrophy-associated genes
was observed. Still in vitro, exposure of endothelial cells to IFN-
I disrupted vascular network organization. All the pathogenic
effects observed in vitro were abolished by ruxolitinib (a
JAK/STAT inhibitor) (51). Finally, in vivo, some refractory
DM patients (in our hands today 10, of whom 4 have been
reported in Ladislau et al. (51) were treated with ruxolitinib,
and improvement ensued in skin lesions, muscle weakness
and reduced serum IFN-I levels and interferon-inducible genes
scores. Apparently, Janus kinase (JAK) inhibition is a promising
mechanism-based treatment for DM, where IFN-I evaluation
(52) (either in the serum and/or in the biopsy) might be a good
biomarker for decision-making (51) (Table 2).
AUTOANTIBODIES AS BIOMARKERS
A comprehensive number of autoantibodies have been identified
both in childhood and in adults IIM: 5 for DM, 8 for
ASS-associated myositis, 2 MSAs for IMNM, and cN1A for
IBM (reviewed in this issue by Feist et al.). It is now
well-established that certain MSAs identify typical clinically
homogeneous subgroups of myositis (1, 2, 12, 53, 54) (Tables 1,
2 and Figures 1–5). Nevertheless, there may be variability in
clinical severity, and also due to ethnical differences and hence
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FIGURE 2 | Characteristic example of anti-Mi2+ DM. (A) Perifascicular atrophy of myofibers (PFA) (H&E stain, original magnification x100). Electron microscopy:
endothelial tubuloreticular inclusions in endothelial cells (original magnification x30.000). (B) Perifascicular MHC class I staining with a decreasing gradient toward the
centrofascicular region (original magnification x200). (C) Perimysial macrophage infiltrate with extension to the endomysium (CD68, original magnification x200). (D)
C5b-9 complement on the sarcolemma of myofibers (original magnification x200).
underlying possible disease susceptibility genes, which may have
an influence on the individuals’ immune system), but this has not
extensively been explored in IIMs yet (55).
Other autoantibodies falling into the group of MAAs
have been associated with certain disease courses, and
pathological presentations e.g. anti-mitochondrial M2 antibodies
in granulomatous diseases (56) and necrotizing myopathy
(Tables 1,2). However most of them like anti-PmSCL or anti-SSa
or SSb and U1RNP have been described regularly in certain
diseases like sclerodermia, Sjögren Syndrome, mixed connective
tissue diseases etc., and we hypothesize that myositis may occur
during these diseases rather than the antibodies occurring
with myositis. Nevertheless, these associations may be very
useful in terms of understanding of the pathogenicity of the
autoantibodies since different “systems” such as muscle, skin,
fibrous tissue, joints, epithelial cells etc. may all have a common
antigenic target, a hypothesis which has not yet been explored in
more detail.
CERTAIN PATTERNS OF HISTOLOGIC
ABNORMALITIES (BIOMARKERS FROM A
MORPHOLOGICAL POINT OF VIEW)
Patterns of histological abnormalities can be very useful for
diagnosis and are used in daily routine in myopathology.
In general, our brain seems to function well in terms of
pattern recognition and a pathologist’s “eye” (& brain) is largely
dependent on pattern recognition and comparison with certain
standards/normals. However, a pattern has to be well-defined
and there may be uncertainty or different definitions among
diagnostic authorities. To unify concepts, it is of high importance
to establish consensus internationally and also to critically
question certain definitions (57–59).
Probably the most well-known morphological “biomarker”
in this respect is the pattern of “perifascicular atrophy” (PFA),
which is used to describe atrophic myofibers in the perifascicular
region (the outer layers of a muscle fascicle in comparison to
the less affected centrofascicular region). Of note, this atrophy
may have various explanations in terms of pathophysiology
and a small fiber may be purely atrophic but also represent
a fiber in regeneration. Fiber atrophy certainly must not be
confounded with fiber necrosis, although regeneration occurs
as a consequence of necrosis and the cause of smallness of a
single regenerating fiber may thus not be identifiable without
having a look at other associated or consecutive features. PFA
is the prime diagnostic feature of dermatomyositis although
some entities may not show PFA so obviously (60) as others,
and PFA is a time-sensible feature, which occurs only after
some time and during progression of the disease. PFA may not
overtly be apparent yet, hence several measures can be taken to
document perifascicular pathology (PFP), which may not only
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FIGURE 3 | Characteristic anti-Jo1-positive ASS-associated myositis. (A) Necrotic myofibers confined to the perifascicular region (H&E stain, original magnification
x200). Electron microscopy: intranuclear actin inclusions in myonuclei (insert; original magnification x20.000). (B) Sarcolemmal MHC class I stain is diffusely positive
(original magnification x200) and MHC class II confined to the sarcolemma and sarcoplams of the perimysial myofibers (insert; original magnification x200). (C)
Lympho-monocytic infiltrate extends into the endomysium (CD68+ macrophages and lymphocytes (original magnification x200). (D) Sarcolemmal C5b-9 and necrotic
myofibers predominant in the perifascicular region (original magnification x200).
be a less controversial nomenclature but also has the advantage
that newer pathophysiological processes can be implemented
(such as Cox paleness informing about mitochondrial pathology,
and MxA stain informing about type I interferon-related
pathology) (Figure 5). PFA can be highlighted by more classical
immunohistochemical stains such as MHC class I stain (showing
a decreasing gradient of staining intensity toward the center of
the fascicles, which can be difficult to see in small fascicles).
Another useful measure is to stain for CD56 and neonatal
Myosin heavy chain (nMyHc) to ascertain affection of the
perifascicular region (Figures 2, 5). In addition, and association
with assessment of PFA, established pathophysiological concepts
of DM such as increased ISGs (see above), can be used to
highlight perifascicular pathology such as stains against MxA or
ISG15, which may even be more sensible to identify DM-specific
(perifascicular) pathology (44) than establishedMHC class 1 (61).
Another useful pattern in terms of perifascicular pathology
may be termed perifascicular necrosis (PFN) highlighting
necrotic muscle fibers predominantly in the perifascicular region
(again compared to the centrofascicular region, which is not
or much less affected). This pattern is characteristic of affected
skeletal muscle in anti-synthetase syndrome (ASS)-associated
myopathies such as those associated with antibodies directed
against Jo1, PL7, PL12, OJ etc. (8–10) (Figure 3). PFN is not a
characteristic feature of DM. In addition to this, MHC class I
is strongly upregulated and can show a perifascicular gradient
similar to DM, however, in case of doubt a helpful stain is
MHC class II, which is strongly present in ASS-associated
myositis and not or only very weakly in DM (8–10, 62).
Complement (C5b-9) staining is widely used in assessment of
IIMs and can stain the sarcolemma and the capillaries. It is
positive on perifascicular muscle fibers sarcolemmally in DM
and ASS-associated myositis (ASSM), hence not allowing any
differentiation between these entities, but it is not positive on
capillaries in ASSM. MxA is constantly absent in ASSM (52). If
complement is identified on the sarcolemma in the perifascicular
region in a patient with DM-typical PFP, diagnosis will be anti-
Mi2+ DM. If predominant complement deposition is identified
on the capillaries it will be anti-TIF1γ+ DM, or more rarely anti-
NXP2+ DM (in adult patients) (Tables 1–3). Complement (C5b-
9) deposition on vessels in association with TIF1γ can be used as a
sensitive prognostic marker of malignancy. This is an example of
combination of several biological parameters increasing cancer
prediction (TIF1γ only 70%, vs. complement on capillaries +
punched-out vacuoles and TIF1γ–positivity 90%) (63) (Table 1
and Figure 5).
Marker molecules of type I Interferon can be used for staining
procedures as well (40, 41, 43, 64). They are strongly positive in
all forms of DM but not or only minimally staining structures
within the skeletal muscle in other IIMs (61), hence these stains
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FIGURE 4 | Characteristic morphology of sIBM. (A) Diffusely distributed necrotic myofibers in a severely myopathic tissue (original magnification x100). (B) Strong
sarcolemmal and sarcoplasmic MHC class I staining (MHC class II fokal stain but no perifascicular pattern) [original magnification x100 (not shown)]. (C) Dense
endomysial lymphocytic infiltrate (original magnification x200). (D) Presence of e.g., p62+ vacuoles in the sarcoplasm (original magnification x200). (E) Mitochondrial
pathology with many COX-negative and SDH-positive fibers (original magnification x400) and paracristalline inclusions on EM (original magnification x20.000). (F)
Electron microscopy: tubulofilaments (original magnification x30.000).
can be effectively used to highlight that ASSM does not fall into
the category of DM and must be regarded as a separate entity
(65). Ultrastructural features can be very useful in diagnosis of
IIMs: Tubuloreticular inclusions (TRIs) in endothelial cells are
an early sign of dermatomyositis (66) and most DM biopsies
irrespective of the associated autoantibody, show TRIs, with
the exception of anti-MDA5 DM which shows TRIs in only
50% (60). TRIs are not specific, but highly sensitive for DM
diagnosis. They can occur in some ASSM and SLE as well as
HIV-associated myopathies, and in rare cases of sIBM TRIs have
been noticed. Again, this is an example of the importance to
combine certain biological parameters increasing their diagnostic
accuracy. Myonuclear actin aggregates have so far only been
found in ASS-associated myositis, mainly in anti-Jo-1+ patients
(8) (Figure 3A, insert). Tubulofilaments associated with vacuoles
and/or in myonuclei are characteristic biological parameters
for sIBM and they are highly specific (Figure 4F), however
their presence is not necessarily required for diagnosis (67).
The authors’ personal conviction is that these ultrastructural
abnormalities have to be searched for thoroughly, and this may
require time and expert knowledge, hence they are very useful
if found.
The diagnosis of sIBM can be made based on clinical
parameters/symptoms: The combination of hip flexor paresis
and subsequent finger flexor paresis associated or not with
swallowing difficulties in an elderly patient is very assuring (28).
Light microscopical biological parameters are the combination
of rimmed vacuoles, severe inflammation, mitochondrial
abnormalities in a severely myopathic “dystrophy-like” biopsy
(fiber necrosis, endomysial fibrosis and severe fiber-size
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FIGURE 5 | Characteristic example of anti-TIF1γ+ DM. Perifascicular pathology of myofibers (PFP) with: (A) atrophic fibers, punched-out vacuoles and violaceous
fibers on Gömöri trichrome (original magnification x100). (B) abundant ghost fibers at the edge of fascicles (original magnification x100). (C) predominant complement
(C5b-9) deposits on capillaries (original magnification x100). (D) MHC class I staining with perifascicular to centrofascicular gradient (original magnification x100). (E)
MxA stain highlighting interferon signature-related pathology predominantly in the perifascicular region (original magnification x100). (F) Presence of COX paleness in
the perifascicular region (original magnification x100).
variation). Additional biological staining parameters are
p62, LC3, desmin, TDP43, and others—however their mere
“presence” is not specific per se, they must show a focal coarse
pattern (68, 69) and their presence in the context of the
above-mentioned clinical picture can be used as a biomarker
informing about a pathophysiological process relevant in this
specific disease (Figure 4). However, congophilic inclusions
within myofibers do not inform about beta amyloid deposits! It
is a widely spread misconception that presence of congophilic
material is equivalent to presence of beta amyloid! On the other
hand, a convincing immunoelectron microscopic study has
shown occasional beta- amyloid in myofibers (70), but this is
not the bulk of amyloidogenic proteins, which may be present
in sIBM (47). Moreover, current proteomic studies have shown
that a multitude of different proteins can be found in vacuoles
of sIBM biopsies, some of which are probably informative
about certain interesting genetic backgrounds such as FYVE
and coiled-coil domain containing 1 (FYCO1) (47) or valosin
containing protein (VCP) (71).
The role of the autoantibody cN1A has been studied by
different groups, and its clinical diagnostic use as a biomarker for
sIBM is now accepted. Presence of the antibody in sIBM informs
about severity of the disease course. However, the antibody has
also been found outside of the context of myopathies in systemic
sclerosis and systemic lupus (71).
FUTURE ASPECTS OF MORPHOLOGICAL
ANALYSIS IN ROUTINE AND RESEARCH
To date, a certain panel of diagnostic stains should be
performed by every myopathologist who reads muscle biopsies
of myositis patients (58). In addition, EM should be performed
in certain cases to increase diagnostic accuracy. New patterns of
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CK × – × +/–
Troponin × – × +/–
KL-6 × – × +/–
IFN signature (serum) × × × ?
IFN signature biopsy × × × ?
Autoantibodies MSA × × × ×
Autoantibodies MAA × – × ×









PFP*** × – × +/–
Degree of Inflammation** × – – –
Distribution of
Inflammation**
× – – –
Distribution of necrotic
myofibers**
× × – –
Complement deposits on
capillaries**
× × × (if considered with
TIF1y in adults >40)
× (if considered
with TIF1y in adults
>40)
Pattern MHC cl I** × × – –
Pattern MHC cl II** × × – –
P62/LC3*** – – – –
IFN signature Biopsy** × × × ?
Endothelial Tubuloreticular
Inclusions**
+ – – –
Nuclear actin filaments** + + – –
Tubulofilaments** + + + +
Level of evidence grade II ** or III***.
ultrastructural analysis such as the myonuclear actin inclusions
may become apparent as we study more biopsies (8).
Combined immunohistochemical or double stains can inform
about certain pathomechanisms linking them to each other
and implementing newer pathophysiological concepts. It has
to be defined if this approach is useful and necessary in
routine diagnosis or if this can be used as biological parameters
in research.
Proteomic approaches can help to identify and define
molecules that are relevant to be studied in more depth
and hence have the potential to become a biomarker for
diagnosis, treatment and/or prognosis (47). Inflammatory
patterns with CD8+ T cells, which surround and/or invade
non-necrotic myofibers have been used traditionally as a
diagnostic marker for IBM and PM. However, this feature is
not at all specific and can be found in numerous monogenic
diseases such as Facioscapulohumeral muscular dystrophy
(FSHD), dysferlinopathy, anoctaminopathy, in lipid storage
myopathies like multiple acyl-coenzyme A dehydrogenase
deficiency (MADD), in toxic myopathies etc. (57). Other patterns
as presence of B cells in clusters or in follicles can be highly
suggestive of DM, and are associated with unfavorable outcome
in jDM (72). B-cell follicles or accumulations can typically occur
in a rare disease called brachiofacial myositis (73), and hence
their presence in the context of the typical clinical picture can
be defined as a biomarker to secure diagnosis of this rare and less
well-known entity.
At presence, we would suggest to consider two of the above-
mentioned biological parameters as relevant and very likely to be
implemented in daily routine:
1. TIF1γ+ dermatomyositis in adults above the age of 40 years,
with a skeletal muscle biopsy showing strong complement
deposition on capillaries, punched-out vacuoles and ghost
fibers can be considered to be highly suggestive of having or
developing a cancer in the course of disease [cancer associated
myositis likeliness between 50 and 90%; 84% in (63)].
2. A characteristic type I interferon signature that can be
highlighted in the skeletal muscle tissue [at present most easily
and reliably identified by staining for MxA (44, 61)].
3. Characteristic morphological phenotypes on muscle biopsies,
which inform about the precise diagnosis of myositis
subentities, best to be used in combination with clinical
and auto-antibody information (this ‘biomarker’ is probably
better called a ‘set of diagnostic features’, which however
is essential to provide the most precise diagnosis we can
provide for patients who may likely need an individualized
therapeutic scheme).
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In the future, successful therapeutic interventions may be used
as biomarkers and secure diagnosis in rare unclear cases as
well. Conversely, we may identify biomarkers informative about
therapeutic success in IIMs as well.
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